Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Transplant Proc ; 56(3): 608-612, 2024 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-38342746

RESUMO

BACKGROUND: Intraoperative cardiac arrest (ICA) during liver transplantation (LT) is a rare surgical complication that results in devastating outcomes. Moreover, previous worldwide studies have found inconsistencies in the risk factors associated with ICA in LT. METHODS: This was a retrospective cohort study of adult patients who underwent LT between January and October 2021 at Siriraj Hospital, a tertiary care hospital. The incidence of ICA and outcomes of patients who experienced ICA were examined. Risk factors associated with ICA were investigated as a secondary objective. RESULTS: Among 342 patients, the incidence of ICA was 3.5% (95% CI 1.8%-6.1%). Of these, 33.3% died intraoperatively. Among patients with ICA, 41.7% died within 30 days, compared with only 7.6% in those without ICA (P = .002). Moreover, the in-hospital mortality rate of those with ICA was 58.3%, which was significantly higher than that of those without ICA (9.7%, P < .001). However, 41.7% of patients with ICA were discharged alive with long-term survival. Because ICA is a rare event, we found only 2 independent factors significantly associated with ICA. These factors include intraoperative temperature below 35°C, with an odds ratio (OR) of 6.07 (95% CI:1.32-27.88, P = .02) and elevated intraoperative serum potassium, with an OR of 4.57 (95% CI:2.15-9.67, P < .001). CONCLUSIONS: ICA is associated with high perioperative and in-hospital mortality. However, our findings suggest that with effective management of ICA, more than 40% of these patients could be discharged with excellent long-term outcomes. Hypothermia and hyperkalemia were independent risk factors significantly associated with ICA.


Assuntos
Parada Cardíaca , Mortalidade Hospitalar , Complicações Intraoperatórias , Transplante de Fígado , Humanos , Transplante de Fígado/efeitos adversos , Transplante de Fígado/mortalidade , Parada Cardíaca/epidemiologia , Parada Cardíaca/etiologia , Fatores de Risco , Masculino , Estudos Retrospectivos , Feminino , Pessoa de Meia-Idade , Incidência , Complicações Intraoperatórias/epidemiologia , Adulto , Resultado do Tratamento , Idoso
2.
J Med Assoc Thai ; 98(8): 775-81, 2015 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-26437535

RESUMO

OBJECTIVE: To study the changes in cortisol levels during and after cardiac surgery after an inductive dose of either etomidate or thiopentone and their consequences. MATERIAL AND METHOD: A prospective, randomized, double-blinded study was conducted in 26 patients undergoing elective cardiac surgery. They received either etomidate or thiopentone for induction. Serum cortisol levels were measured preoperatively, and then at 2-, 4-, 8-, and 24-hour All of the patients received standard anesthesia and surgery. The data also included patients perioperative management and outcome. RESULTS: There is no difference in patients' characteristics. The baseline plasma morning cortisols in the two groups were comparable (11.7 ± 7.5 mcg/dL in etomidate group vs. 12.0 ± 8.2 mcg/dL in thiopentone group). In both groups, during surgery, the cortisol levels rose to higher levels and reached peak levels at four to eight hours and related to surgical stress. At all times, the etomidate group had lower cortisol levels but only at 8-hour the etomidate group had significantly lower cortisol level (39.9 ± 14.2 vs. 65.9 ± 20.0 mcg/dL). At 24 hours, in both groups, cortisol levels were lower than at 8-hour but did not return to normal baseline levels. There were no differences in the dose of inotropic use and ICU stay. However surprisingly the etomidate group had shorter hospital stay. CONCLUSION: A single dose of etomidate usedfor induction in elective cardiac patients can partially and reversibly inhibit of the cortisol synthesis for, at least, 24 hours, but its association with any hemodynamic consequences cannot be concluded. REGISTRATION: ClinicalTrials.gov as NCT01495949.


Assuntos
Anestésicos Intravenosos/uso terapêutico , Procedimentos Cirúrgicos Cardíacos/métodos , Procedimentos Cirúrgicos Eletivos/métodos , Etomidato/uso terapêutico , Hidrocortisona/sangue , Tiopental/uso terapêutico , Idoso , Anestésicos Intravenosos/efeitos adversos , Método Duplo-Cego , Etomidato/efeitos adversos , Hemodinâmica , Humanos , Tempo de Internação , Pessoa de Meia-Idade , Estudos Prospectivos , Tiopental/efeitos adversos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA